Piramal Healthcare India Ltd formerly known as Nicholas Piramal India Ltd (NPIL) is a major player in formulations, diagnostics and vitamins in the Indian pharma industry besides having good export presence. Its formulations field force of 2,778 personnel is one of the largest in the country. According to ORG-IMS, NPIL was the second fastest growing company in the domestic formulations market.
Nicholas Piramal India Limited is one of India's largest companies with an unmatched record of managing JVs/Alliances/Partnerships, and a proven commitment to IPR. With strong brand management and sales capabilities, a US FDA site-approved plant for on-and-off patent APIs and Intermediates, Basic Research, Process Innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and a world-class, accredited Clinical Research Organisation, NPIL is poised to emerge as India's pharma powerhouse.
With growth fuelled through a strategy of partnerships, quality acquisitions, brand building, focused selling and manufacturing,
NPIL has emerged among the leaders in Indian pharma with a unique mix of inorganic and organic growth fuelled through a strategy of acquisitions, brand building and focused selling, and manufacturing. The company has one of the widest product portfolios in India, spanning nine key therapeutic areas, including the Cardio-vascular, Neuro-psychiatry, Oncology, Diabetes Management, Respiratory, Anti-infectives, Gastro-intestinals, Dermatology and NSAIDS.
The company was formed when the Piramal Group acquired Nicholas Laboratories, a small formulations company in 1988 from Sara Lee. It has followed a multi-pronged strategy to integrate and maximize synergies with the planned acquisitions and develop and consolidate its major strength in marketing to therapeutic niches.
Managed by a team of highly proficient industry professionals, NPIL's key strengths come from its strong brand building, selling and distribution, manufacturing and alliance/partnership management skills. The last, especially, are quite unique in the Indian context - few Indian Pharmaceutical have exhibited such a strong and consistent record in successfully and ethically managing JVs/Alliances and Partnerships as NPIL has.
Its policy of respecting IPR and managing partnerships, in keeping with both the letter and the spirit of written agreements, has been widely respected and commended by its partners.
NPIL is the flagship company of the Rs. 2500 crore (US $ 550 million) Piramal Enterprises (PEL), one of India's largest diversified business houses.
Novo Nordisk. It’s a Denmark based healthcare MNC and it comes among top 4 pharmaceutical companies all over the world. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.
Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 79 countries, and markets its products in 180 countries.
Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.. They have recently shifted their Clinical Data Management Setup from Singapore to Bangalore. Novo Nordisk ROFE is one of the fastest growing business areas of Region International Operations. ROFE (Region Office Far East) is located in Bangalore and it takes care of operations in 14-16 south east Asian countries.
Countries represented by ROFE are Bangladesh, Bhutan, Brunei, Cambodia, India, Indonesia, Laos, Malaysia, Maldives, Myanmar, Nepal, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, and Vietnam.
Novo Nordisk is known in the industry for their work-culture. They are a team of thorough professionals. They provide excellent training to their employees.
Serum Institute of India Ltd. has established it's self as the world's largest producer of Measles and DTP group of vaccines. It is estimated that two out of every three children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute. In fact, our range of products have been used in 140 countries across the globe.
Serum Institute of India was founded in 1966 with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines.
The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Rabies vaccine, Combination vaccine etc., so that not only Indian's, but the entire under-privileged children of the world, in more than 140 countries are protected from birth onwards
Serum Institute of India have recently set up Serum Bio Pharma Park, India's first biotech Special Economic Zone (SEZ). The Park is adjoining Serum Institute's existing manufacturing unit and is a sector-specific SEZ meant for biotechnology and pharmaceutical products. The SEZ will allow Serum Institute of India to avail various tax benefits such as income tax, import duty on capital goods etc. This has encouraged a lot of foreign companies to partner with Serum Institute of India to avail and share these benefits.
It is highly professionally managed company with excellent work culture.
Serum institute of India has got in agreement with US based firm AKORN to market their oncology drugs for US market. They have recently set-up their regulatory office in Latin America.
Ferring is a Swiss-based biopharmaceutical company active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, infertility, obstetrics, and urology. Having over 2500 employees worldwide and operating subsidiaries in over 40 countries.
Indian Operations began with the establishment of Ferring Pharmaceuticals Pvt. Ltd., in 1997. Ferring products with international brands are manufactured in Switzerland, Germany, Denmark, Sweden, and Czech Republic & United States. People come first at Ferring Because: Patients using our products and physicians prescribing them have a right to expect: that we will only make available those products in which we have full confidence. that we will offer the best possible products at the most reasonable cost. that Ferring’s employees will always display courtesy and respect, and act professionally.
Jubilant Organosys is an integrated pharmaceuticals industry player having its presence across the pharmaceuticals value chain. We are a collaborative and innovative provider of products and services to the global life sciences industry, striving to accelerate the process of pharmaceutical drug approval.
Jubilant Organosys is one of the largest custom research and manufacturing services (CRAMS) companies, a leading active pharmaceuticals ingredients player and the largest drug discovery services provider out of India. Jubilant Organosys has presence across the pharmaceuticals value chain right from drug discovery services which include bioinformatics, chemistry services and clinical research to custom research and manufacturing for advance intermediates, fine chemicals and active pharmaceutical ingredients and dosage forms.
Jubilant Organosys has a knowledge base of more than 25 years in chemistry to produce innovative products and processes by leveraging our R&D expertise, knowledge driven operations and global scale manufacturing capacities.
Jubilant Organosys has three subsidiary companies in India - Jubilant Biosys Ltd. for bio / chemo informatics databases, Jubilant Chemsys Ltd. for chemistry services and Jubilant Clinsys Ltd. for clinical research. Jubilant Organosys has a strong international presence having international subsidiaries in Belgium, USA and China. Jubilant acquired PSI & PSI Supply in Belgium - the companies providing regulatory affairs services and supply of dosage forms, Trigen Laboratories Inc. - a US generic pharmaceuticals company and Clinsys Inc. – a full service clinical research organization. Jubilant products are sold across the globe in more than 60 countries.
Biocon is a fully integrated healthcare company that delivers innovative biopharmaceutical solutions. From discovery to development and commericalisation, we have the defining science, cost-effective drug development capabilities and significant manufacturing capacity to move ideas to market.
Leveraging India’s globally competitive cost base and exceptional scientific people resource, we are advancing our in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through our subsidiary companies, Syngene and Clinigene.
Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain. With the successful commercial launch of our first anti-cancer drug and several promising discovery partnerships in the clinic, we remain committed to scaling new heights in frontier science and achieving new milestones in affordable medicine
Biocon is India's leading biotechnology enterprise. Over the past 28 years, Biocon has evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, focused on healthcare. Biocon applys its proprietary fermentation technologies to develop innovative and effective biomolecules in diabetology, oncology, cardiology and other therapeutic segments.
At Biocon, success has been ability to develop innovative technologies and products and to rapidly leverage them to adjacent domains. This unique "integrated innovation" approach has yielded a host of patented products and technologies that have enabled multi-level relationships with our global clientele.
